Edited by Yuriy L Orlov and Ancha V Baranova
Volume 19 Supplement 1
Publication of this supplement has not been supported by sponsorship. Information about the source of funding for publication charges can be found in the individual articles. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editors declare that they were not involved in the peer review for any article on which they are an author.
Novosibirsk, Russia07-10 August 2017
Citation: BMC Neuroscience 2018 19(Suppl 1):14
Optogenetics has become widely recognized for its success in real-time control of brain neurons by utilizing non-mammalian photosensitive proteins to open or close membrane channels. Here we review a less well...
Citation: BMC Neuroscience 2018 19(Suppl 1):12
The dominant hypothesis about the pathogenesis of Alzheimer’s disease (AD) is the “amyloid cascade” concept and modulating the expression of proteins involved in the metabolism of amyloid-beta (Aβ) is propose...
Citation: BMC Neuroscience 2018 19(Suppl 1):13
APOE ε4 allele is most common genetic risk factor for Alzheimer’s disease (AD) and cognitive decline. However, it remains poorly understood why only some carriers of APOE ε4 develop AD and how ethnic variabilitie...
Citation: BMC Neuroscience 2018 19(Suppl 1):16
A challenge of understanding the mechanisms underlying cognition including neurodevelopmental and neuropsychiatric disorders is mainly given by the potential severity of cognitive disorders for the quality of ...
Citation: BMC Neuroscience 2018 19(Suppl 1):22
63 days to first decision for reviewed manuscripts only
54 days to first decision for all manuscripts
193 days from submission to acceptance
12 days from acceptance to publication
120 Altmetric Mentions